Annals of Surgical Oncology

, Volume 24, Issue 4, pp 1037–1045 | Cite as

Impact of Skeletal Muscle Mass, Muscle Quality, and Visceral Adiposity on Outcomes Following Resection of Intrahepatic Cholangiocarcinoma

  • Shinya Okumura
  • Toshimi Kaido
  • Yuhei Hamaguchi
  • Atsushi Kobayashi
  • Hisaya Shirai
  • Yasuhiro Fujimoto
  • Taku Iida
  • Shintaro Yagi
  • Kojiro Taura
  • Etsuro Hatano
  • Hideaki Okajima
  • Shinji Uemoto
Hepatobiliary Tumors

Abstract

Background

Decrease in skeletal muscle mass and function, known as sarcopenia, is associated with poor prognosis. Visceral fat accumulation also is related to mortality. This study investigated the impact of preoperative skeletal muscle mass, muscle quality, and visceral adiposity on outcomes in patients undergoing resection of intrahepatic cholangiocarcinoma (ICC).

Methods

A retrospective analysis was performed of 109 patients undergoing resections of ICC between January 2004 and April 2015. Skeletal muscle mass [skeletal muscle index (SMI)], skeletal muscle quality [muscle attenuation (MA)], and visceral adiposity [visceral to subcutaneous adipose tissue area ratio (VSR)] were measured on preoperative computed tomography images. The impacts of these parameters on outcomes after ICC resections were analyzed.

Results

The overall survival rates were significantly lower in patients with low SMI (P = 0.002), low MA (P = 0.032), and high VSR (P = 0.026) compared with patients with high SMI, high MA, and low VSR, respectively. With multivariate analyses, in patients with stage I–III, low SMI (hazard ratio (HR) 3.29, P = 0.003) and low MA (HR 2.86, P = 0.010) were revealed as independent significant risk factors for mortality. In patients with stage IV, none of these parameters was identified as risk factors, with only the absence of adjuvant chemotherapy identified as an independent risk factor for mortality (HR 5.92, P = 0.001).

Conclusions

Although stage was the most important factor, low skeletal muscle mass and quality were closely related to mortality after resection of ICC in patients with stage I–III.

Abbreviations

AUC

Area under the curve

BMI

Body mass index

CI

Confidence interval

CRP

C-reactive protein

CT

Computed tomography

HCC

Hepatocellular carcinoma

HR

Hazard ratio

HU

Hounsfield Unit

ICC

Intrahepatic cholangiocarcinoma

LT

Liver transplantation

MA

Muscle attenuation

OS

Overall survival

RFS

Recurrence-free survival

ROC

Receiver operating characteristic

SMI

Skeletal muscle index

TNM

Tumor node metastasis

UICC

Union for International Cancer Control

VSR

Visceral to subcutaneous adipose tissue area ratio

Supplementary material

10434_2016_5668_MOESM1_ESM.docx (98 kb)
Supplementary material 1 (DOCX 97 kb)

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg. 2009;208:134–47.CrossRefPubMedGoogle Scholar
  3. 3.
    Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40:472–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.CrossRefPubMedGoogle Scholar
  6. 6.
    Morizane C, Okusaka T, Mizusawa J, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013;104:1211–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Farges O, Fuks D, Le Treut YP, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group. Cancer. 2011;117:2170-7.CrossRefPubMedGoogle Scholar
  8. 8.
    Sakamoto Y, Kokudo N, Matsuyama Y, et al. Proposal of a new staging system for intrahepatic cholangiocarcinoma: analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer. 2016; 122:61–70.CrossRefPubMedGoogle Scholar
  9. 9.
    Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127:990s–991s.PubMedGoogle Scholar
  10. 10.
    Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in older people. Age Ageing. 2010;39:412–23.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Muscaritoli M, Anker SD, Argiles J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr. 2010;29:154–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for sarcopenia. J Am Med Dir Assoc. 2014;15:95–101.CrossRefPubMedGoogle Scholar
  13. 13.
    Harimoto N, Shirabe K, Yamashita YI, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg. 2013;100:1523–30.CrossRefPubMedGoogle Scholar
  14. 14.
    van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg. 2012;99:550–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Kaido T, Ogawa K, Fujimoto Y, et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. Am J Transplant. 2013;13:1549–56.CrossRefPubMedGoogle Scholar
  16. 16.
    Zoico E, Corzato F, Bambace C, et al. Myosteatosis and myofibrosis: relationship with aging, inflammation and insulin resistance. Arch Gerontol Geriatr. 2013;57:411–6.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Marcus RL, Addison O, Kidde JP, Dibble LE, Lastayo PC. Skeletal muscle fat infiltration: impact of age, inactivity, and exercise. J Nutr Health Aging. 2010;14:362–6.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hamaguchi Y, Kaido T, Okumura S, et al. Impact of quality as well as quantity of skeletal muscle on outcomes after liver transplantation. Liver Transpl. 2014;20:1413–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Hamaguchi Y, Kaido T, Okumura S, et al. Preoperative intramuscular adipose tissue content is a novel prognostic predictor after hepatectomy for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2015;22:475-85.CrossRefPubMedGoogle Scholar
  20. 20.
    Okumura S, Kaido T, Hamaguchi Y, et al. Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Surgery. 2015;157:1088–98.CrossRefPubMedGoogle Scholar
  21. 21.
    Okumura S, Kaido T, Hamaguchi Y, et al. Impact of the preoperative quantity and quality of skeletal muscle on outcomes after resection of extrahepatic biliary malignancies. Surgery. 2016;159:821–33.CrossRefPubMedGoogle Scholar
  22. 22.
    Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. Jama. 2007;298:2028–37.CrossRefPubMedGoogle Scholar
  23. 23.
    van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomark Prev. 2009;18:2569–78.CrossRefPubMedGoogle Scholar
  24. 24.
    Moon HG, Ju YT, Jeong CY, et al. Visceral obesity may affect oncologic outcome in patients with colorectal cancer. Ann Surg Oncol. 2008;15:1918–22.CrossRefPubMedGoogle Scholar
  25. 25.
    Okamura A, Watanabe M, Mine S, et al. Clinical impact of abdominal fat distribution on prognosis after esophagectomy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2016;23:1387-94.CrossRefPubMedGoogle Scholar
  26. 26.
    Fujiwara N, Nakagawa H, Kudo Y, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 2015;63:131-40.CrossRefPubMedGoogle Scholar
  27. 27.
    Dindo D, Demartines N, Clavien P-A. Classification of Surgical Complications. Annals of Surgery. 2004;240:205–13.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998;85:115–22.Google Scholar
  29. 29.
    Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629–35.CrossRefPubMedGoogle Scholar
  30. 30.
    Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8:457–65.CrossRefPubMedGoogle Scholar
  31. 31.
    Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest. 2007;117:2362–8.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11:11–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Lutz CT, Quinn LS. Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism. Aging (Albany NY). 2012;4:535–46.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Freese KE, Kokai L, Edwards RP, et al. Adipose-derived stems cells and their role in human cancer development, growth, progression, and metastasis: a systematic review. Cancer Res. 2015;75:1161–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6:772–83.CrossRefPubMedGoogle Scholar
  36. 36.
    Benzo R, Wigle D, Novotny P, et al. Preoperative pulmonary rehabilitation before lung cancer resection: results from two randomized studies. Lung Cancer. 2011;74:441–5.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Mayo NE, Feldman L, Scott S, et al. Impact of preoperative change in physical function on postoperative recovery: argument supporting prehabilitation for colorectal surgery. Surgery. 2011;150:505–14.CrossRefPubMedGoogle Scholar
  38. 38.
    Inoue J, Ono R, Makiura D, et al. Prevention of postoperative pulmonary complications through intensive preoperative respiratory rehabilitation in patients with esophageal cancer. Dis Esophagus. 2013;26:68–74.CrossRefPubMedGoogle Scholar
  39. 39.
    Delmonico MJ, Harris TB, Visser M, et al. Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr. 2009;90:1579–85.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Goodpaster BH, Carlson CL, Visser M, et al. Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. J Appl Physiol. 2001;90:2157–65.PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2016

Authors and Affiliations

  • Shinya Okumura
    • 1
  • Toshimi Kaido
    • 1
  • Yuhei Hamaguchi
    • 1
  • Atsushi Kobayashi
    • 1
  • Hisaya Shirai
    • 1
  • Yasuhiro Fujimoto
    • 1
  • Taku Iida
    • 1
  • Shintaro Yagi
    • 1
  • Kojiro Taura
    • 1
  • Etsuro Hatano
    • 1
  • Hideaki Okajima
    • 1
  • Shinji Uemoto
    • 1
  1. 1.Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of MedicineKyoto UniversityKyotoJapan

Personalised recommendations